Solid Biosciences Inc - ESG Rating & Company Profile powered by AI
Alternative companies in the rating industry group for Solid Biosciences Inc are shown. The assessment of Solid Biosciences Inc was prepared by All Street Sevva using advanced Cognitive Robots. Detailed Sustainability analysis of Solid Biosciences Inc are reached by registering for free.
Solid Biosciences Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.3; made up of an environmental score of 1.6, social score of 3.2 and governance score of 8.0.
4.3
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Novartis AG | 9.2 | High |
2 | Daiichi Sankyo Co Ltd | 8.9 | High |
1284 | Sinopep Allsino Bio Pharmaceutical Co Ltd | 4.4 | High |
1284 | Vanda Pharmaceuticals Inc | 4.4 | High |
1335 | Solid Biosciences Inc | 4.3 | High |
1335 | Angion Biomedica Corp | 4.3 | High |
1335 | AddLife AB | 4.3 | High |
... | ... | ... | |
2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
2749 | Zyden Gentec Ltd | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Solid Biosciences Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Solid Biosciences Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Solid Biosciences Inc report the average age of the workforce?
Sign up for free to unlockDoes Solid Biosciences Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Solid Biosciences Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Solid Biosciences Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Solid Biosciences Inc offer flexible work?
Sign up for free to unlockDoes Solid Biosciences Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Solid Biosciences Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Solid Biosciences Inc conduct supply chain audits?
Sign up for free to unlockDoes Solid Biosciences Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Solid Biosciences Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Solid Biosciences Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Solid Biosciences Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Solid Biosciences Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Solid Biosciences Inc disclose water use targets?
Sign up for free to unlockDoes Solid Biosciences Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Solid Biosciences Inc have a product recall in the last two years?
Sign up for free to unlockDoes Solid Biosciences Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Solid Biosciences Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Solid Biosciences Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Solid Biosciences Inc disclose parental leave metrics?
Sign up for free to unlockDoes Solid Biosciences Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Solid Biosciences Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Solid Biosciences Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Solid Biosciences Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Solid Biosciences Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Solid Biosciences Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Solid Biosciences Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Solid Biosciences Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Solid Biosciences Inc disclose its waste policy?
Sign up for free to unlockDoes Solid Biosciences Inc report according to TCFD requirements?
Sign up for free to unlockDoes Solid Biosciences Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Solid Biosciences Inc disclose energy use targets?
Sign up for free to unlockDoes Solid Biosciences Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Solid Biosciences Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Solid Biosciences Inc
These potential risks are based on the size, segment and geographies of the company.
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.